Chuanxiong type compounds for preventing cardiovascular diseases
Referencias
Additional references
American Heart Association. Heart Disease and Stroke Statistics (available at http://www.americanheart.org/downloadable/heart/1105390918119HDSStats2005Update.pdf accessed April 2005). Dallas. Texas: American Heart Association, 2005 Update.
American Stroke Association. Impact of Stroke. Available at http://www.strokeassociation.org/presenter.jhtml?identifier=1033 [accessed April 2005}.
Antithrombotic Trialists' Collaboration. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71‐86.
Bonita R, Stewart A, Beaglehole R. International trends in stroke mortality: 1970‐1985. Stroke 1990;21(7):989‐92.
Chen JC, Min Y, Wang GQ, Wang Y, Ji JM, Zhang Y. Comparing the effect of anti platelet aggregation of Nao An capsule to aspirin. Chinese Journal of Clinical Pharmaology 1998;7(3):144‐5.
Chen JC, Min Y, Wang GQ, Ji JM, Wang Y, Zhang Y. The action of Nao An capsule for brain vessel of rabbit. Chinese Journal of Clinical Pharmocology 1998;7(5):236‐7.
Chen KJ. Ligustrazine's chemical and pharmacological property and clinical application. Beijing: People's Health Publication House, 1999. [R971/13‐3]
Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286‐91.
Hacke W, Kaste M, Skyhoj Olsen T, Bogousslavsky J, Orgogozo JM, for the EUSI Executive Committee. The European Stroke Initiative ‐ Reducing the Incidence & Impact of Stroke. Available at http://www.eusi‐stroke.com/prevention.php?cid=7 accessed in 14 Aug. 2007.
Gao BT, Hu ZX, Li CY. The influence on platelet aggregation of terramethylpyrazine and aspirin in the patients with ischaemic stroke. Chinese Journal of Neurology and Psychiatry 1989;22(3):148‐51.
Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association. Stroke 2001;32(1):280‐99.
Gorelick PB. Stroke prevention. Archives of Neurology 1995;52:347‐55.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. http://www.cochrane.org/resources/handbook/hbook.htm [accessed 22 Feb 2007].
Huang ZF, Zhao L, Gong XW. Protective effects of ligustrazine on hypoxic‐ischemic brain damage in neonatal rates. Chinese Journal of Practical Chinese and Western Medicine 2004;4(17):2545‐7.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. CFR & ICH Guidelines. Vol. 1, Philadelphia: Barnett International/PAREXEL, 1997.
Jia M, Xie L, Liu G, Wu T. Chuanxiong‐type preparation for acute ischemic stroke. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005569]
Lampert N, Xu Y. Chinese herbal nephropathy. Lancet 2002;359(9308):796‐7.
Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium, 20‐24 Oct 1996 Adelaide, Australia. 1996.
Lin XL, Xu GY, Zhang ZJ, Murong CX, Chen YZ, Ding LX, et al. Observation for influence on platelet aggregation and blood viscosity of terramethylpyrazine in the treatment of patient with acute stroke. Journal of Fujian Medical Colleage 1991;25(1):36‐7.
Lin R, Liu JT, Gan WJ, Wang WR. Effect of ligustrazine on injury of vascular endothelial cells ECV‐304 included by hypoxia and lack of glucose. China Journal of Chinese Materia Medica 2004;29(5):2004.
Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001;358(9292):1515‐6.
Mei JJ, Cai DY, Zhao YX, Tian WH, Ye GM, Chen ZF, et al. An experimental study for the mechanism of ligustrazine preventing and treating atherosclerosis. Journal of Hubei College of Traditional Chinese Medicine 2004;6(2):5‐7.
National Health and Medical Research Concil, Australian. Prevention of Stroke, A Guide for General Practitioner. http://www.nhmrc.gov.au/publications/pdf/cp47.pdf [accessed at 21 April, 2005]. Australian Government Publishing Service, 1996. [ISBN 0 644 47591 9]
Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). New England Journal of Medicine 2000;342(23):1686‐92.
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low‐dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine 2005;352(13):1293‐304. [MEDLINE: 15753114]
Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000185.pub2.]
Tan ZY, Jiang T, Tang CP, Luo JL, Tan HT, Chen RS. The inhibitory effect of tetramethylpyrazine ferulate on platelet aggregation. Chinese Journal of New Drugs 2003;12(7):529‐31.
Tang GH, Jiang GH, Wang SZ, Zheng LF. Studies on synthesis and pharmacological activity of ferul ic acid salts. Chinese Pharmacology Journal 1999;34(10):697‐9.
Wang LJ, Chen W, Yu RH, Mao L, Ding XY, Wang GQ, et al. Clinical observation for effect of Nao An capsule improving brain vascular function. Journal of Clinical Neurology 2004;17(6):476‐7.
Wu GX, Wu ZS, He BL, Zhang M, Zhang RS, Qin LP, et al. Epidemiological characteristics of stroke in 16 provinces of China. National Medical Journal of China 1994;74(5):281‐3, 285.
Wu GX, Wu ZS, Liu J, Zhen ZC, Wang WH, Qin LP, et al. Trends of stroke events during 15 years in Beijing (WHO‐SINO‐MONICA Project Studies). Chinese Journal of Prevention and Control of Chronic Non‐Communicable Diseases 2001;9(3):106‐8.
Wu TX, Liu GJ. The concepts, design, practice and report of allocation concealment and blinding. Chinese Journal of Evidence‐Based Medicine 2007;7(3):219‐22.
Xiao J, Luo HL, Wang ZR, Guo HL, Bao DY, Feng XM, et al. A study of terramethylpyrazine influence blood rheological indicators of rabbit. Journal of West China University of Medical Sciences 1994;25(4):463.
Xiao YQ, Li L, You XL, Taniguchi M, Baba K. Studies on Chemical Constituents of the Rhizomae of Ligusticum chuanxiong. China Journal of Chinese Materia Medica 2002;27(2):519‐22.
Yan J. The current epidemiological status and burden of chronic diseases in China. Chinese Journal of Prevention and Control of Chronic Non‐Communicable Diseases 1998;6(2):49‐51.
Zhou ZY, Xiao Y, Wang WG, Chen YM. Clinical observation for "Zhong Fang" powder in the prevention of stroke. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai 1999;13(3):26‐8.
